1 / 6

Patients with LBBB and LV dysfunction

Study Design. Patients qualifying for CRT. Responders. Patients with LBBB and LV dysfunction. Patients with Narrow / Normal QRS. 0. 100. Study Design. Overall Objective

cmuldrow
Download Presentation

Patients with LBBB and LV dysfunction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Study Design Patients qualifying for CRT Responders Patients with LBBB and LV dysfunction Patients with Narrow / Normal QRS 0 100

  2. Study Design Overall Objective Determine CRT safety and efficacy in patients who are indicated for an ICD with NYHA Class III, narrow QRS duration (<130 ms) and evidence of mechanical dyssynchrony as measured by echocardiography/Tissue Doppler Imaging Primary Endpoint Improvement in Peak VO2 during CPET of at least 1.0ml/kg/min at 6 months. Secondary Endpoints Improvement in QoL score at 6-months Improvement in NYHA classification at 6-months

  3. Efficacy Analysis/Study Flow A total of 156 (80 Control + 76 CRT) were available for efficacy analysis

  4. Quality of Life % Improved in Peak VO2 Median & 95% Conf Int 100 70 p = 0.91 p = 0.63 80 60 60 46% 50 41% 40 40 20 30 0 Baseline 6-months Control CRT NYHA Class Six-minute Hall Walk Distance (m) Median & 95% Conf Int 100 p = 0.23 p = 0.006 80 400 64% 60 54% 350 41% 40 29% 20 300 8% 5% 0 Improved No Change Worsened Baseline 6-months 250 Control (n = 80) Control (n = 80) CRT (n = 76) CRT (n = 76) Efficacy Data

  5. QRS Duration Cardiomyopathy Type 100 100 p = 0.45 p = 0.02 p = 0.82 p = 0.25 80 80 60 60 Peak VO2 (% improved from baseline) (% improved from baseline) 40 40 20 20 0 0 QRS < 120 ms QRS ≥ 120 ms Ischemic Non-ischemic Control (n = 80) CRT (n = 76) Peak VO2 by sub-group

  6. Conclusion • In this randomized controlled trial, CRT did not improve Peak VO2 during exercise in patients with NYHA Class III heart failure, QRS duration <130ms, and an EF ≤ 35%. • However, the subgroup of patients with QRS duration between 120 ms and 130 ms benefited from CRT. • Additional research will be critical to further our understanding of the role of CRT in this patient population.

More Related